Zevra Therapeutics (ZVRA) said Monday that it has completed the sale of a rare pediatric disease priority review voucher for $150 million in gross proceeds.
Zevra had received the voucher last year following US regulatory approval of its therapy for Niemann-Pick type C, Miplyffa, the commercial-stage company said.
The funds will be used to support the commercial launches of Miplyffa and Olpruva, ongoing clinical studies on celiprolol, and overall investment plans, the company said.
As of March 31, Zevra reported preliminary cash and equivalents of $68.7 million, which would rise to $217 million after accounting for post-quarter net proceeds from the sale.
Shares of the company were down more than 3.5% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.